This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
Quite no common agreement on the place for pharmaceutical sampling. I suspect that, since consensus has been so difficult to achieve, there are some very valid, though differing, viewpoints to be heard. Perhaps if several viewpoints are presented and thoughtfully considered, consensus might be achieved or, lacking that, a clearer understanding of the issues will be gained.
I welcome the opportunity to present a viewpoint in this forum. While it fairly reflects the view of my company, Westwood Pharmaceuticals Inc (Buffalo), I would not presume to speak for any other company. I would suspect, however, that many of my observations will find general agreement among my colleagues in industry.
First of all, I think it is important to recognize that the relationship between the physician and the pharmaceutical companies is a very special one. I feel this is particularly true in dermatology. We provide products that will help practitioners treat
French WD. A Delicate Balance: A Perspective on Pharmaceutical Sampling. Arch Dermatol. 1988;124(4):588–589. doi:10.1001/archderm.1988.01670040080030
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: